These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Grippo PJ; Fitchev PS; Bentrem DJ; Melstrom LG; Dangi-Garimella S; Krantz SB; Heiferman MJ; Chung C; Adrian K; Cornwell ML; Flesche JB; Rao SM; Talamonti MS; Munshi HG; Crawford SE Gut; 2012 Oct; 61(10):1454-64. PubMed ID: 22234980 [TBL] [Abstract][Full Text] [Related]
46. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model. Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772 [TBL] [Abstract][Full Text] [Related]
47. Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer. Yuan F; Sun M; Liu Z; Liu H; Kong W; Wang R; Qian F Theranostics; 2022; 12(3):1061-1073. PubMed ID: 35154474 [No Abstract] [Full Text] [Related]
48. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009 [TBL] [Abstract][Full Text] [Related]
49. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627 [TBL] [Abstract][Full Text] [Related]
50. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associated miR-503/CDKN2A regulatory axis. Li ZY; Zhu SS; Chen XJ; Zhu J; Chen Q; Zhang YQ; Zhang CL; Guo TT; Zhang LM Biochem Biophys Res Commun; 2017 Nov; 493(2):1018-1025. PubMed ID: 28942143 [TBL] [Abstract][Full Text] [Related]
51. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop. Fujimura K; Wang H; Watson F; Klemke RL Cancer Res; 2018 Mar; 78(6):1444-1456. PubMed ID: 29321164 [TBL] [Abstract][Full Text] [Related]
53. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes. Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072 [TBL] [Abstract][Full Text] [Related]
54. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer. Liu H; Qian F Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489 [TBL] [Abstract][Full Text] [Related]
55. Requirement of NEMO/IKKγ for effective expansion of KRAS-induced precancerous lesions in the pancreas. Maier HJ; Wagner M; Schips TG; Salem HH; Baumann B; Wirth T Oncogene; 2013 May; 32(21):2690-5. PubMed ID: 22751123 [TBL] [Abstract][Full Text] [Related]
56. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423 [TBL] [Abstract][Full Text] [Related]
57. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation. Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853 [TBL] [Abstract][Full Text] [Related]
58. Critical role of hnRNP A1 in activating KRAS transcription in pancreatic cancer cells: A molecular mechanism involving G4 DNA. Cogoi S; Rapozzi V; Cauci S; Xodo LE Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1389-1398. PubMed ID: 27888145 [TBL] [Abstract][Full Text] [Related]
59. Drugging the Next Undruggable KRAS Allele-Gly12Asp. Zheng Q; Peacock DM; Shokat KM J Med Chem; 2022 Feb; 65(4):3119-3122. PubMed ID: 35167298 [TBL] [Abstract][Full Text] [Related]
60. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer. Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]